Method of detection of new contralateral primary breast cancer in younger versus older women

Clinical Breast Cancer

Volumn 7, Issue 9, 2007, Pages 705-709

  Robinson, Andrew ^a   Speers, Caroline ^b   Olivotto, Ivo ^b   Chia, Stephen ^b  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Estrogen receptor; Magnetic resonance imaging; Mammography

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONSET AGE; PROGNOSIS;

EID: 34548358845     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.030     Document Type: Article

References (26)

1. Khatcheressian JL, Woff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091-5097.
2. Grunfeld E, Dhesy-Thind S, Levine M, et al. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ 2005; 172:1319-1320.
3. Li CI, Malone K, Porter PL, et al. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 2003; 89:513-518.
4. Foxcroft LM, Evans EB, Porter AJ. The diagnosis of breast cancer in women younger than 40. Breast 2004; 13:297-306.
5. British Columbia Cancer Agency. Cancer Management Guidelines. Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Breast/ ScreeningEarlyDetection.htm. Accessed June 1, 2007.
6. Ringash J. Preventive health care, 2001 update: screening mammography among women aged 40-49 years at average risk of breast cancer. CMAJ 2001; 164:469-476.
7. Moss S, Waller M, Anderson TJ, et al. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. BJC 2005; 92:955-960.
8. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:1769-1778.
9. Hartman AR, Daniel BL, Kurian AW, et al. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer 2004; 100:479-489.
10. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:8469-8476.
11. de Koning HJ. Mammographic screening. Evidence from randomized controlled trials. Ann Oncol 2003; 14:1185-1189.
12. Olivotto IA, Kan L, d'Yachkova Y, et al. Ten years of breast screening in the Screening Mammography Program of British Columbia, 1988-97. J Med Screen 2000; 7:152-159.
13. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24:2437-2443.
14. Komenaka IK, Ditkoff BA, Joseph KA, et al. The development of interval breast malignancies in patients with BRCA mutations. Cancer 2004; 100:2079-2083.
15. Schaapveld M, Willemse PH, de Vries EG, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer occurrence. A population based study. J Clin Oncol 2005; 23(16 suppl):8s (Abstract #518).
16. Ji J, Hemminki K. Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat 2006 [Epub ahead of print].
17. Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of Surveillance, Epidemiology, and End Results data. J Clin Oncol 2005; 23:5534-5541.
18. Rawal R, Lorenzo Bernejo J, Hemminki K. Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening. Br J Cancer 2005; 92:162-166.
19. Kirova YM, Stoppa-Lyomet D, Savignoni A, et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005; 41:2304-2311.
20. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22:2328-2335.
21. Cook LS, White E, Schwartz SM, et al. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control 1996; 7:382-390.
22. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271.
23. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995; 87:645-651.
24. Pisano ED, Gatsonis C, Hendrick E, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005; 353:1773-1783.
25. Lehman CD, Blume JD, Thickman D, et al. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol 2005; 92:9-15.
26. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:1317-1325.